- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01675856
Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB)
Urgent vs. Early Endoscopy in High Risk Patients With UGIB
Acute upper gastrointestinal bleeding (UGIB) is one of the commonest medical emergencies. The condition accounts for 150 per 100,000 populations. A National United Kingdom reported a crude overall mortality rate of 10%. While bleeding stops spontaneously in majority of patients at their presentation, there remains a subgroup of patients who continue to bleed or develop recurrent bleeding. In these patients, the mortality increases manifolds. If these high-risk patients can be identified, early interventions may improve their outcomes.
Several prognostic indices are in use for the purpose of patient stratification. They include the Rockall, Glasgow-Blatchford (GBS) and the Baylor scores. The Rockall score is a composite score which incorporates clinical parameters as well as findings during endoscopy which was derived to predict mortality. The GBS is a pre-endoscopy or a clinical score for the prediction for the need of further intervention loosely defined as the need for transfusion, endoscopy or surgery. It has been shown to be accurate in identifying low risk patients for early discharge.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, China
- Endoscopy Centre, Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overt signs of upper gastrointestinal bleeding (i.e., melena or hematemesis with or without hypotension)
- GBS of ≥12
- In-patients admitted for reasons other than AUGIB who develop bleeding are also considered for trial enrollment.
- Patients in Hypotensive shock (SBP ≤90 mmHg or pulse ≥110 bpm) are initially resuscitated and then considered for trial entry if their condition can be stabilized.
Exclusion Criteria:
- continued shock despite initial volume resuscitation (refractory shock) undergo urgent endoscopy
- < 18 years of age
- Unable to provide written informed consent
- Pregnant or lactating women
- Moribund patients from terminal illnesses. (active treatment not considered)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Urgent endoscopy
Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
|
Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
|
|
Placebo Comparator: Early endoscopy
Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
|
Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: 30 days
|
Death from all causes 30 days from randomization
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Need for endoscopic therapy at index endoscopy
Time Frame: At the time of index endoscopy
|
To measure if endoscopic therapy is needed at the index endoscopy
|
At the time of index endoscopy
|
|
Need for transfusion
Time Frame: Within 30days of randomization
|
To measure if transfusion of blood products is needed within 30days of randomization
|
Within 30days of randomization
|
|
Recurrent bleeding as defined
Time Frame: Within 30days of randomization
|
To measure if any clinical or endoscopic recurrent bleeding is identified.
|
Within 30days of randomization
|
|
Duration of hospital stay of index bleeding
Time Frame: Within 30 days of randomization
|
To measure the number of days of hospital stay upon randomization, only counted the hospitalization days of index bleeding.
|
Within 30 days of randomization
|
|
ICU stay
Time Frame: Within 30days of randomization
|
To measure if ICU admission is required at the index bleeding.
|
Within 30days of randomization
|
|
Need for further endoscopic treatment
Time Frame: Within 30days of randomization
|
To measure if further endoscopic treatment if required at recurrent bleeding
|
Within 30days of randomization
|
|
Emergency surgery or interventional radiology to achieve hemostasis
Time Frame: Within 30days of randomization
|
To measure if emergency surgery or interventional radiology is needed at index bleeding or recurrent bleeding to achieve hemostasis
|
Within 30days of randomization
|
|
Rates of recurrent bleeding
Time Frame: Within 30 days of randomization
|
To measure recurrent bleeding in both study arms
|
Within 30 days of randomization
|
|
Rate of adverse events
Time Frame: Within 30 days of randomization
|
To measure the adverse events in either group, e.g.
myocardial event, cerebrovascular event and acute renal failure.
|
Within 30 days of randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Y Lau, MD, Chinese University of Hong Kong
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUGIB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Bleeding
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Tanta UniversityRecruitingCirrhosis | Variceal Bleeding | Upper Gastrointestinal Bleeding (UGIB)Egypt
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Next Biomedical Co., Ltd.Not yet recruitingLower Gastrointestinal Bleeding | Diverticular BleedingKorea, Republic of
-
National University of SingaporeRecruitingGastroIntestinal BleedingSingapore
-
Next Biomedical Co., Ltd.CompletedGastroIntestinal BleedingKorea, Republic of
-
General Hospital of Shenyang Military RegionRecruitingAcute Upper Gastrointestinal Bleeding | Acute Variceal BleedingChina
-
Tallaght University HospitalRecruitingUpper Gastrointestinal BleedingSpain
Clinical Trials on Urgent endoscopy
-
Beijing 302 HospitalCompletedCirrhosis | Gastrointestinal Endoscopy | Variceal Bleeding | Upper Gastrointestinal HemorrhageChina
-
Mahidol UniversityEnrolling by invitationLower Gastrointestinal Bleeding | Small Bowel BleedingThailand
-
Beijing Anzhen HospitalNot yet recruitingCoronary Heart Disease | Acute Non-variceal Upper Gastrointestinal Hemorrhage
-
Uroplasty, IncCompletedUrinary Bladder, OveractiveUnited States
-
Uroplasty, IncCompletedOveractive BladderUnited States
-
Fundació Institut de Recerca de l'Hospital de la...CompletedEmergencies | Surgery--ComplicationsSpain
-
Maastricht University Medical CenterCompletedFecal IncontinenceNetherlands, France, Italy
-
Uroplasty, IncTerminated
-
Karolinska InstitutetSahlgrenska University Hospital, SwedenRecruitingPostoperative Cognitive Dysfunction | Cardiac Surgery | Postoperative RecoverySweden
-
Hospital San Carlos, MadridHospital General Universitario Gregorio Marañon; Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital and other collaboratorsCompleted